Psychiatry Partnering & Dealmaking Reviewed in New Research Study Recently Published at MarketPublishers.com09 May 2012 • by Natalie Aster
LONDON – The majority of psychiatry partnering deals in the biopharma industry are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors psychiatry technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Knowing the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what is expected to be achieved during the negotiation of terms. While smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered.
New research study “Psychiatry Partnering Terms and Agreements” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.
Psychiatry Partnering Terms and Agreements
Published: March, 2012
Price: US$ 2.695,00
The report provides an enhanced understanding and access to over 1,000 psychiatry partnering deals and agreements entered into by the world’s leading healthcare companies. Top psychiatry deals by value are examined, key trends in psychiatry partnering deals are analyzed, most active psychiatry dealmakers are revealed, and listing of deals by headline value, upfront payment value, royalty rate value, stage of development at signing, deal component type, technology type, and specific therapy indication is provided within the study.
More new research studies by the publisher can be found at CurrentPartnering page.